Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 M IN DEXTROSE 10 IN PLASTIC CONTAINER versus HEPATAMINE 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 M IN DEXTROSE 10 IN PLASTIC CONTAINER versus HEPATAMINE 8.
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER vs HEPATAMINE 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% M in Dextrose 10% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The amino acids undergo transamination, deamination, and incorporation into body proteins. Dextrose is metabolized via glycolysis, the Krebs cycle, and oxidative phosphorylation to produce ATP.
HEPATAMINE 8% is a branched-chain amino acid (BCAA) solution that provides leucine, isoleucine, and valine to correct amino acid imbalances in hepatic encephalopathy. It reduces plasma aromatic amino acids (AAA) and increases BCAA, restoring the BCAA/AAA ratio, which decreases false neurotransmitter synthesis in the brain.
Intravenous infusion via central line. Adult dose: 500-2000 mL/day (equivalent to 21.25-85 g amino acids and 50-200 g dextrose) based on caloric and nitrogen requirements. Rate not to exceed 100 mL/hour initially, adjusted to maintain blood glucose <200 mg/dL.
Intravenous infusion: 125 mL/hr initially, titrate to achieve positive nitrogen balance; typical adult dose: 125 mL/hr to 250 mL/hr via central line, not to exceed 2 g protein equivalent per kg per day.
None Documented
None Documented
Amino acids: variable; individual amino acid half-lives range from minutes to hours; dextrose: 1-2 hours; clinical context: continuous infusion required to maintain stable plasma levels.
Variable; amino acids in HEPATAMINE 8% are cleared rapidly (t1/2 ~10-20 minutes for free amino acids) due to endogenous metabolism. In hepatic failure, half-life may be prolonged (patients with cirrhosis: up to 60 minutes for certain amino acids). Clinical context: supports continuous infusion for stable plasma levels.
Renal: amino acids are metabolized and nitrogen is excreted primarily as urea (80-90%) and ammonia (minor); dextrose is fully metabolized to CO2 and water; negligible biliary/fecal elimination.
Renal: negligible as intact amino acids; nitrogen waste (urea) excreted renally (80-90% of infused nitrogen). Biliary/fecal: <5%.
Category C
Category C
Amino Acid Solution
Amino Acid Solution